We are live on ! Find out more
BC

Birchview Capital Portfolio holdings

AUM $176M
1-Year Est. Return 95.04%
This Fund
S&P 500
This Quarter Est. Return
-7.77%
1 Year Est. Return
+95.04%
3 Year Est. Return
+233.14%
5 Year Est. Return
+280.2%
10 Year Est. Return
+1,023.63%
AUM
$150M
AUM Growth
-$15.8M
Cap. Flow
+$2.4M
Cap. Flow %
1.6%
Top 10 Hldgs %
78.1%
Holding
51
New
–
Increased
6
Reduced
3
Closed
1

Top Buys

Rank Stock Value
1
QDEL icon
QuidelOrtho
QDEL
+$1.72M
2
BMY.RT
Bristol-Myers Squibb Company Contingent Value Rights
BMY.RT
+$1.43M
3
ACAD icon
Acadia Pharmaceuticals
ACAD
+$389K
4
ALBO
Albireo Pharma Inc
ALBO
+$291K
5
AMRN
Amarin Corp
AMRN
+$240K

Top Sells

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$769K
2
AWH
Aspira Women's Health Inc. Common Stock
AWH
+$709K
3
NARI
Inari Medical, Inc. Common Stock
NARI
+$193K
4
WKHS icon
Workhorse Group
WKHS
+$114K

Sector Composition

Rank Sector Weight
1 Healthcare 95.26%
2 Energy 1.16%
3 Consumer Discretionary 0.13%
4 Consumer Staples 0.1%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BMY icon
1
Bristol-Myers Squibb
BMY
$124B
$47.9M 32%
794,386
+2,000
+0.3% +$120K
AXDX
2
DELISTED
Accelerate Diagnostics
AXDX
$23.4M 15.62%
219,380
– –
QDEL icon
3
QuidelOrtho
QDEL
$1.18B
$12.9M 8.6%
58,644
+7,700
+15% +$1.72M
AWH
4
DELISTED
Aspira Women's Health Inc. Common Stock
AWH
$9.51M 6.36%
206,007
-13,809
-6% -$709K
NBIX icon
5
Neurocrine Biosciences
NBIX
$17.5B
$7.5M 5.01%
78,000
– –
ACAD icon
6
Acadia Pharmaceuticals
ACAD
$4.32B
$4.21M 2.81%
102,000
+9,000
+10% +$389K
BLUE
7
DELISTED
bluebird bio
BLUE
$3.24M 2.16%
4,632
– –
BIIB icon
8
Biogen
BIIB
$30B
$3.12M 2.08%
11,000
– –
BMY.RT
9
DELISTED
Bristol-Myers Squibb Company Contingent Value Rights
BMY.RT
$2.71M 1.81%
1,206,848
+500,000
+71% +$1.43M
KPTI icon
10
Karyopharm Therapeutics
KPTI
$153M
$2.45M 1.64%
11,200
– –
XLRN
11
DELISTED
Acceleron Pharma
XLRN
$2.1M 1.4%
18,672
– –
SLNO
12
DELISTED
Soleno Therapeutics
SLNO
$2.08M 1.39%
55,127
– –
OXFD
13
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
$1.99M 1.33%
170,303
– –
ALBO
14
DELISTED
Albireo Pharma Inc
ALBO
$1.94M 1.29%
58,000
+10,000
+21% +$291K
MASI
15
DELISTED
Masimo
MASI
$1.89M 1.26%
8,000
– –
UTHR icon
16
United Therapeutics
UTHR
$22.6B
$1.82M 1.21%
18,000
– –
ARNA
17
DELISTED
Arena Pharmaceuticals Inc
ARNA
$1.65M 1.1%
22,000
– –
CCXI
18
DELISTED
ChemoCentryx, Inc.
CCXI
$1.64M 1.1%
30,000
– –
MYOK
19
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$1.36M 0.91%
10,000
– –
CFRX
20
DELISTED
ContraFect Corporation
CFRX
$1.35M 0.9%
3,196
– –
AMRN
21
Amarin Corp
AMRN
$286M
$1.26M 0.84%
15,000
+2,000
+15% +$240K
ETRN
22
DELISTED
Equitrans Midstream Corporation Common Stock
ETRN
$1.13M 0.75%
133,050
– –
HROW icon
23
Harrow
HROW
$1.68B
$1.01M 0.67%
180,000
– –
CORT icon
24
Corcept Therapeutics
CORT
$9.88B
$870K 0.58%
50,000
– –
EPZM
25
DELISTED
Epizyme, Inc
EPZM
$835K 0.56%
70,000
– –
1
2 3

Similar funds

RWA
Resolute Wealth Advisor Findlay, Ohio $176M AUM
BAM
Boyar Asset Management New York $176M AUM 20.04% 1-Year Est. Return
TIM
Tevis Investment Management Plano, Texas $176M AUM 18.14% 1-Year Est. Return
TFCM
Taylor Frigon Capital Management Scottsdale, Arizona $176M AUM 24.25% 1-Year Est. Return
FPW
Flywheel Private Wealth Los Altos, California $176M AUM 26.12% 1-Year Est. Return
LWM
Lifetime Wealth Management Rockwall, Texas $176M AUM
PFA
Providence Financial Advisors Overland Park, Kansas $175M AUM
DAM
Draper Asset Management Smithtown, New York $176M AUM 37.45% 1-Year Est. Return

Birchview Capital's Q3 2020 Portfolio in Review

As of Q3 2020, Birchview Capital held 51 positions worth $150M, down 9.5% from $165M the previous quarter. Its ten largest holdings account for 78% of the portfolio.

Trading was light in Q3 2020: portfolio turnover was 2%. Birchview Capital opened no new positions and exited 1, leaving the 51-position portfolio largely intact.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 96% a quarter earlier, followed by Energy and Consumer Discretionary.

  • Birchview Capital added most to QuidelOrtho in Q3 2020, an estimated $1.72M increase.
  • Birchview Capital's biggest Q3 2020 reduction was Aspira Women's Health Inc. Common Stock, cutting an estimated $709K.
  • Birchview Capital fully exited Gilead Sciences in Q3 2020, selling an estimated $769K.
  • Birchview Capital's ten largest holdings make up 78% of its $150M portfolio in Q3 2020.
  • Birchview Capital opened 0 new positions and closed 1 in Q3 2020.
  • Birchview Capital's portfolio value fell 9.5% quarter-over-quarter to $150M.

Based on Birchview Capital's 13F filing for Q3 2020, filed 12 Nov 2020.